Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids

Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs), such as trabectedin. Hence, we evaluated the capability of trabectedin to inhibit CC viability and used ovarian cancer (OC) m...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fonte, Roberta, Strippoli, Sabino, Garofoli, Marianna, Cormio, Gennaro, Serratì, Simona, Loizzi, Vera, Fasano, Rossella, Arezzo, Francesca, Volpicella, Mariateresa, Derakhshani, Afshin, Guida, Michele, Porcelli, Letizia, Azzariti, Amalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294430/
https://www.ncbi.nlm.nih.gov/pubmed/37384250
http://dx.doi.org/10.3389/fcell.2023.1178316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294430/
https://www.ncbi.nlm.nih.gov/pubmed/37384250
http://dx.doi.org/10.3389/fcell.2023.1178316

Ejemplares similares